MTAP and renal cell carcinoma: This study utilized RCC samples from large-scale, global, multicenter sequencing cohorts and first proved that genomic alteration of MTAP/CDKN2A significantly correlates with sarcomatoid differentiation in RCC and predicts aggressive progression, poor prognosis, primary resistance to targeted therapy, and potential favorable responses to immune checkpoint blockade.